• FPH1 (BRD-6125) for Reliable Hepatocyte Proliferation Assays

  2026-05-09

  FPH1 (BRD-6125) enables reproducible, donor-independent expansion of functional human hepatocytes—addressing a critical bottleneck in drug screening and cell therapy workflows. This guide details optimized protocols, troubleshooting strategies, and workflow bridges to emerging gene therapy models.

• IGF2BP3 Stabilizes EPOR mRNA to Drive AML Progression via m6

  2026-05-08

  Fan et al. (2023) establish IGF2BP3 as a key m6A reader that stabilizes EPOR mRNA, activating JAK/STAT signaling and promoting acute myeloid leukemia (AML) progression. Their integrative analysis and prognostic gene signature offer new directions for risk assessment and therapeutic targeting in AML.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mic

  2026-05-08

  This study systematically investigates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and liver distribution of key Corydalis saxicola Bunting alkaloids, elucidating the impact of disease state on drug metabolism. Findings highlight that pathological changes and PXR-mediated modulation of CYP450s and transporters drive significant pharmacokinetic variability, with direct implications for optimizing therapeutic regimens in chronic liver disease.

• (-)-Blebbistatin: Bridging Mechanotransduction and Translati

  2026-05-07

  This in-depth article explores the cutting-edge role of (-)-Blebbistatin as a non-muscle myosin II inhibitor in unraveling mechanotransduction mechanisms, with a focus on its application in GABA-independent signaling, cytoskeletal research, and translational workflows. Drawing on new findings in GABAB receptor activation by mechanical forces, the piece offers strategic guidance for researchers seeking to leverage mechanistic insights for disease modeling and therapeutic innovation.

• In Vitro Susceptibility of Staphylococci to Mupirocin and No

  2026-05-07

  This study systematically assessed the in vitro susceptibility of meticillin-resistant and meticillin-susceptible staphylococci from healthy and diseased dogs to mupirocin and novobiocin, identifying substantial efficacy yet variable resistance patterns among staphylococcal isolates. The findings inform evolving antimicrobial stewardship strategies in veterinary settings, emphasizing the need for ongoing susceptibility monitoring and comparative research.

• QSHXO Mitigates MASLD via Autophagy Activation and Ferroptos

  2026-05-06

  This study elucidates the dual mechanism by which Qushi Huoxue ointment (QSHXO) alleviates metabolic associated steatotic liver disease (MASLD), highlighting its activation of autophagy and suppression of ferroptosis in hepatocytes. These findings advance mechanistic understanding of MASLD therapy and provide a foundation for targeting cellular stress pathways in chronic liver disease.

• (S)-Mephenytoin: Transforming CYP2C19 Assays in Organoid Mod

  2026-05-06

  This thought-leadership article explores how (S)-Mephenytoin is accelerating the evolution of CYP2C19 substrate assays in advanced in vitro pharmacokinetic workflows, especially as hiPSC-derived intestinal organoids become the gold standard for human-relevant drug metabolism studies. Grounded in mechanistic evidence and strategic guidance, it highlights best practices, protocol parameters, and future implications for translational researchers.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ) in Calcium Signaling

  2026-05-05

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) enables precise modulation of ER calcium dynamics, advancing both stem cell mobilization and vascular research. Recent breakthroughs highlight its pivotal role in enhancing hematopoietic stem cell yields, positioning BHQ as a transformative tool for calcium signaling investigations.

• Targeting FGFR2 Fusion in ICC via Heteroduplex Oligonucleoti

  2026-05-05

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (HDO) that specifically targets FGFR2 fusion oncogenes in intrahepatic cholangiocarcinoma (ICC). It demonstrates that combining targeted FGFR2 inhibition with asparagine deprivation can overcome resistance mechanisms, providing a rationale for new therapeutic strategies.

• E. coli Uracil-DNA Glycosylase (UDG): Practical Lab Applicat

  2026-05-04

  E. coli Uracil-DNA Glycosylase (UDG) is a recombinant enzyme designed for the removal of uracil from DNA, minimizing carryover contamination in PCR and supporting DNA repair research. It should be used exclusively in scientific research workflows and is not suitable for RNA substrates, diagnostic, or clinical applications.

• Flubendazole (SKU B1759) for Reliable Autophagy Modulation

  2026-05-04

  This article addresses persistent challenges in cell viability and autophagy assays by analyzing real laboratory scenarios where Flubendazole (SKU B1759) provides reproducible, data-backed solutions. Readers will learn when and why to use this high-purity, DMSO-soluble autophagy activator in cancer biology and neurodegenerative disease research, ensuring methodological rigor and workflow efficiency.

• Coumestrol: Phytoestrogen Estrogen Receptor Antagonist Advan

  2026-05-03

  Coumestrol’s dual role as a phytoestrogen estrogen receptor antagonist and inducer of ferroptosis in rheumatoid arthritis synoviocytes unlocks new frontiers for nuclear receptor and inflammation research. This article details protocol best practices, advanced assay applications, and troubleshooting insights, drawing from pivotal recent studies and APExBIO’s rigorously characterized product.

• Rapamycin (Sirolimus): Precision mTOR Inhibition in Cell Ass

  2026-05-02

  Rapamycin (Sirolimus) enables robust and targeted mTOR pathway inhibition for advanced research in cancer biology, immunology, and mitochondrial disease models. This guide translates recent mechanistic and workflow insights—including from TDG-ATF4-mTORC1 research—into actionable protocols and troubleshooting strategies for reproducible, high-impact experiments.

• Tiamulin (Thiamutilin): Comparative Metabolism and Assay Des

  2026-05-01

  Explore the unique metabolic pathways and practical assay implications of Tiamulin (Thiamutilin), a pleuromutilin antibiotic for veterinary use. This article provides a comparative perspective grounded in recent UHPLC–Q/TOF research, enabling more precise protocol design for infectious disease and anti-inflammatory models.

• HCN4 S4-S5 Linker Motif Drives Cardiac Heat Response Mechani

  2026-05-01

  Wu et al. (2023) reveal that a conserved S4-S5 linker motif in HCN4 channels is essential for heart rate acceleration in response to heat, independent of the classical cAMP binding pathway. This finding clarifies the molecular basis of temperature-induced cardiac excitability, offering a refined perspective for future studies on heart rate regulation.

15624 records 1/1042 page Next 12345 下5页 Last page